# A Study to Evaluate the Safety, Tolerability, and Blood Levels of PF-03654746 in Subjects With Mild to Moderate Alzheimer's Disease

> **NCT01028911** · PHASE1 · TERMINATED · sponsor: **Pfizer** · enrollment: 9 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** PF-03654746
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01028911
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-12
- **Primary completion:** 2010-05
- **Final completion:** 2010-05
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** This study terminated 27Apr2010 due to slow recruitment and the need to use the existing information to determine dosing for another study.
- **Last updated:** 2014-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01028911

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01028911, "A Study to Evaluate the Safety, Tolerability, and Blood Levels of PF-03654746 in Subjects With Mild to Moderate Alzheimer's Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01028911. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*